← back to search

Daniel Cimbora

Amgen (United States) · US
Area of research
Pathology and Forensic Medicine · Cell Biology
Research interest
Research interests include Multiple Sclerosis Research Studies, Microtubule and mitosis dynamics, Peripheral Neuropathies and Disorders, and Genomics and Chromatin Dynamics.
h-index
26
citations
3,789
works
56
NIH funding
primary concept
email

Recent publications

Inebilizumab for Treatment of IgG4-Related Disease
New England Journal of Medicine 2024cited by 103position: middledoi
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
The Lancet Neurology 2024cited by 49position: middledoi
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
Journal of Neurology Neurosurgery & Psychiatry 2023cited by 42position: middledoi
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of <scp><i>FCGR3A</i></scp> polymorphism
Annals of Clinical and Translational Neurology 2023cited by 18position: middledoi
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial
EBioMedicine 2022cited by 39position: middledoi
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study
Multiple Sclerosis and Related Disorders 2021cited by 52position: middledoi
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
Neurology Neuroimmunology & Neuroinflammation 2021cited by 39position: middledoi
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder
Multiple Sclerosis and Related Disorders 2021cited by 34position: middledoi
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD
Multiple Sclerosis Journal 2021cited by 17position: middledoi
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
The Lancet 2019cited by 711position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Bruce Cree · California State University, Bakersfield9 papers (2019–2024)Dewei She · Amgen (United States)9 papers (2019–2024)Jeffrey L. Bennett · University of Colorado Denver8 papers (2019–2024)Eliezer Katz · Psyadon Pharmaceuticals (United States)8 papers (2019–2024)Brian G. Weinshenker · Mayo Clinic8 papers (2019–2024)Orhan Aktaş · Düsseldorf University Hospital8 papers (2019–2024)Friedemann Paul · Max Delbrück Center8 papers (2019–2024)Hans‐Peter Hartung · The University of Sydney8 papers (2019–2024)Ho Jin Kim · National Cancer Center8 papers (2019–2024)Dean M. Wingerchuk · University of Colorado Denver7 papers (2019–2024)William A. Rees · Mayo Clinic7 papers (2021–2024)Gary Cutter · Epilepsy Foundation7 papers (2019–2024)Romain Marignier · Hospices Civils de Lyon7 papers (2019–2024)Ari Green · University of California, San Francisco6 papers (2019–2024)Kazuo Fujihara · Fukushima Medical University6 papers (2019–2024)Michael Smith · Amgen (United States)6 papers (2021–2024)Jörn Drappa · University of California, San Francisco5 papers (2019–2021)John N. Ratchford · Amgen (United States)4 papers (2019–2021)Sean J. Pittock · Mayo Clinic4 papers (2021–2024) · 3 papers (2019–2021)